Rating reports

The International Finance Facility for Immunisation (IFFIm) is rated AA/Aa1/AA

Rating reports

Rating Information 

IFFIm has been rated AA/Aa1/AA by FitchRatings, Moody's Investor Service and Standard & Poor's based principally on:      

  • the high credit quality of its donors and their legally binding commitments;
  • its politically compelling mandate to support immunisation and vaccination in developing countries;
  • its conservative financial policies and financial and risk management by the World Bank.

Download rating reports

Fitch Ratings: credit analysis report, December 2016

Standard & Poor's: research update, December 2016

Fitch Ratings: credit update, December 2016

Moody's: credit analysis, July 2016

Standard & Poor's: research update, July 2016

Fitch Ratings: Press Release, June 2016

Standard & Poor’s rating report, April 2016

Standard & Poor's: research update, December 2015

Fitch Ratings: credit analysis report, December 2015

Moody's - IFFIm 2015 credit analysis, July 2015

Standard & Poor's bulletin, January 2015

Standard & Poor's: rating report, December 2014

Fitch Ratings: Press Release, December 2014

Standard & Poor's: research update, November 2014

Moody's Investors Service: credit opinion, August 2014

FitchRatings: Full ratings report, April 2014

Standard & Poor's rating report, March 2014

Fitch Ratings: credit analysis report, December 2013

Moody's Investor Service: credit analysis, December 2013

Standard & Poor’s: research update November 2013

Standard & Poor's rating report, May 2013

Fitch Ratings action April 2013

Moody's Investors Service: rating action March 2013

Moody's - IFFIm 2012 credit analysis, December 2012

Standard & Poor's: research update, December 2012

Fitch Ratings: credit analysis report, December 2012

Moody's Investors Service: announcement, June 2012

Standard & Poor's: research update, May 2012

Standard & Poor's: research report, February 2012

Standard & Poor’s: research update, January 2012

Moody’s Investors Service: credit analysis, December 2011

Standard & Poor's: research update, December 2011

Fitch Ratings: credit update, November 2011

Fitch Ratings: credit analysis report, December 2010

Standard & Poor's: research update, November 2010

Standard & Poor's: rating report, September 2010

Moody's Investors Service: credit opinion, September 2009

+40%

Over the course of a decade, the weighted average price of pentavalent vaccine (DTP-hepB-Hib) dropped by 43% from US$ 3.56 per dose in 2003 to US$ 2.04 per dose in 2013, with a lowest-ever price of US$ 1.19 from one supplier in 2013.

Gavi

More facts...

close icon

modal window here